CELLphenomics and Charles River announce agreement, expanding 3D in vitro services for cancer therapy drug screening

Berlin, Germany and Wilmington, Mass., Jan. 9, 2024 – CELLphenomics and Charles River Laboratories International, Inc. (NYSE: CRL) announced an agreement, that provides Charles River clients with access to CELLphenomics’ proprietary 3D tumor model platform, PD3D®, which will expand Charles River’s 3D in vitro testing services to further optimize oncological approaches for its clients. CELLphenomics’ core competence is the […]

CELLphenomics, KYAN Technologies and Alentis Therapeutics join forces

Berlin, Singapore, Allschwil 9-29-2023 CELLphenomics and KYAN Technologies, a vanguard combinatory drug development solutions provider, are thrilled to announce a strategic partnership with Alentis Therapeutics, a clinical-stage biopharmaceutical company developing breakthrough treatments for Claudin-1 positive tumours and organ fibrosis. This partnership aims to accelerate research into Claudin-1 expression using innovative patient-derived 3D (PD3D®) cell culture […]

New publication in Molecular Cancer

Berlin, Germany, 6-23-2023 Large quantities of the protein IGF2BP2 not only make bowel cancer grow faster, but they also make it resistant to common forms of chemotherapy. This discovery was made by a research team led by Martin Luther University Halle-Wittenberg (MLU) and Saarland University with the collaboration of CELLphenomics. For its new study, published […]

Kyan Therapeutics and CELLphenomics announce new partnership

Berlin/Singapore 4-14-2023  CELLphenomics and KYAN Therapeutics announced their new partnership today. By combining KYAN’s technology platform, Optim.AI™ – which utilizes artificial intelligence to predict the effects of drug combinations and CELLphenomics‘ proprietary PD3D® technology, this partnership aims to offer an efficient approach to expedite drug development process in the biopharmaceutical industry. The combination of these […]

Indivumed and CELLphenomics announce their new partnership

Berlin/Hamburg, Germany, 9-7-2022 The Indivumed GmbH and the CELLphenomics GmbH today announced a partnership to create a unique platform for faster and more efficient discovery and validation of therapeutic targets. The new platform combines Indivumed’s AI-driven oncology analytics with CELLphenomics’ expertise in creating organoid models to identify therapeutically relevant targets and validate these targets in-vitro. The partnership […]